USPTO serial 78713173
Reviewed by CopyMark Law Group
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Plus Government fees of $2,600
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
Associated Regional and University Pathologists, Inc.
Salt Lake City, UT, US
Other trademarks owned by Associated Regional and University Pathologists, Inc.
SALT LAKE CITY, UT, US
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lester K. Essig
Lester K. Essig Ray Quinney & Nebeker36 South State StreetSuite 1400Salt Lake City, UT 84111| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business consultation services for laboratory, medical and health care organizations, hospitals and providers in the fields of promotion, marketing, marketing materials, marketing development, market research, market surveys, sales development, sales training, laboratory service directories, brand development, business development, contract negotiations, competition, business plans, laboratory services, placing orders for laboratory services, supply and storage of laboratory goods, delivery of laboratory goods, courier services, referrals, third party service providers, factors to consider in selecting third party service providers, laboratory specimen flow audits, laboratory process efficiency, patient care, patient service centers, customer service, customer loyalty, physician connectivity, result delivery, employee hiring, employee retention, employee motivation, fee schedules, billing, laboratory cost analysis, and business cost analysis | ACTIVE | Sep 30, 1995 |
| 041 | Educational services, namely arranging and conducting classes, seminars, conferences, workshops and discussions, and distributing educational materials, brochures and reports in connection there with, in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microwave processing, microscopy, electron microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, health care, and child health care; and educational services, namely arranging and conducting training and classes for laboratory, medical and health care organizations, hospitals and providers in the fields of promotion, marketing, marketing materials, marketing development, market research, market surveys, sales development, sales training, laboratory service directories, brand development, business development, contract negotiations, competition, business plans, laboratory services, placing orders for laboratory services, supply and storage of laboratory goods, delivery of laboratory goods, courier services, referrals, third party service providers, factors to consider in selecting third party service providers, laboratory specimen flow audits, laboratory process efficiency, patient care, patient service centers, customer service, customer loyalty, physician connectivity, result delivery, employee hiring, employee retention, employee motivation, fee schedules, billing, laboratory cost analysis, and business cost analysis | ACTIVE | Sep 30, 1995 |
| 042 | Clinical laboratory services, reference laboratory services, dissection laboratory services, diagnostic laboratory services, medical laboratory services, and veterinary laboratory services, all in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microwave processing, microscopy, electron microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, health care, and child health care; clinical laboratory services, reference laboratory services, dissection laboratory services, diagnostic laboratory services, medical laboratory services, veterinary laboratory services, and medical and scientific research, namely, collecting, processing, treating, freezing, staining, dissecting, analyzing, screening, testing, typing and storing of biological substances and human and animal tissue, blood, blood components, cells, stems cells, abnormal cells, chromosomes and nucleic acid; development, improvement, evaluation, analysis and application of clinical laboratory tests and diagnostics in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microwave processing, microscopy, electron microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, health care and child health care; medical research in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microwave processing, microscopy, electron microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, health care, and child health care; and medical laboratory services, namely, providing laboratory information online over a global communications network in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microwave processing, microscopy, electron microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, health care, and child health care | ACTIVE | Sep 30, 1995 |
| 044 | Maintaining files and records concerning the medical condition of individuals | ACTIVE | Sep 30, 1995 |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 28, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 28, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 29, 2017 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Dec 29, 2017 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Dec 29, 2017 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Dec 29, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 1, 2017 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Dec 18, 2013 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED | — |
| Dec 18, 2013 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Dec 18, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 6, 2013 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Dec 6, 2013 | PAPER RECEIVED | — | |
| Mar 20, 2013 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 19, 2008 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Feb 14, 2008 | PLGL | ASSIGNED TO PARALEGAL | — |
| Dec 20, 2007 | AMD7 | SEC 7 REQUEST FILED | — |
| Dec 20, 2007 | PAPER RECEIVED | — | |
| Dec 4, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 2, 2007 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Oct 4, 2007 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 18, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 12, 2007 | PAPER RECEIVED | — | |
| Aug 29, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 10, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 10, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 10, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 10, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Aug 9, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 9, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 9, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 22, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 16, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 5, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 2, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 29, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jun 28, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 28, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 28, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 28, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 8, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 8, 2007 | ALIE | ASSIGNED TO LIE | — |
| May 22, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 22, 2007 | PAPER RECEIVED | — | |
| Feb 5, 2007 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 5, 2007 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 23, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 18, 2006 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 23, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 20, 2006 | ALIE | ASSIGNED TO LIE | — |
| Oct 13, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 20, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 12, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2006 | PAPER RECEIVED | — | |
| Jun 14, 2006 | NAUD | NOTICE OF UNRESPONSIVE AMENDMENT - MAILED | — |
| Jun 13, 2006 | NAUD | REPORT UNRESPONSIVE AMENDMENT - COMPLETED | — |
| May 23, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| May 11, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 11, 2006 | PAPER RECEIVED | — | |
| Mar 24, 2006 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 8, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 22, 2005 | NWAP | NEW APPLICATION ENTERED | — |